GO
Loading...

The push back on Sovaldi

Friday, 25 Jul 2014 | 2:52 PM ET

Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.